Biopharma Stock Flashing 'Buy' Signal

ECYT stock has more than quintupled since its February lows

Managing Editor
Sep 20, 2018 at 2:34 PM
facebook X logo linkedin


Endocyte, Inc. (NASDAQ:ECYT) stock is up 1% at $17.71 in afternoon trading -- and if past is prologue, the biopharmaceutical concern could be headed even higher soon. Below we will dig deeper into the security's technical performance, and learn why now may be the perfect time to bet on ECYT's next leg higher. 

ECYT has been in rally mode since touching its early February low of $2.81, so far adding 530%. The security touched a four-year high of $20.85 on Sept. 4, but has since pulled back to its 40-day moving average, which has been a "buy" signal in the past.

Daily Chart of ECYT with 40MA

Endocyte stock is now within one standard deviation of its 40-day moving average. Over the past three years, there have been six prior instances of ECYT pulling back to this trendline after closing north of it at least 60% of the time during the previous two months and in eight of the last 10 trading days. Those prior pullbacks have resulted in an average one-month return of 14.85%, per data from Schaeffer's Senior Quantitative Analyst Rocky White, with 80% of those returns positive. A bounce of this magnitude would push Endocyte shares back above $20, within a chip-shot of a fresh multi-year peak.

Short interest on ECYT fell 26.7% during the past two reporting periods, but still represents nearly 13% of the stock's total available float. At the biopharma concern's average daily trading volume, it would take shorts about a week to buy back the rest of their bearish bets -- plenty of fuel for a short squeeze.

Meanwhile, the stock's Schaeffer's Volatility Index (SVI) of 62% ranks in the 2nd percentile of its annual range, which indicates short-term options are cheap, from a volatility perspective. Plus, ECYT sports a Schaeffer's Volatility Scorecard (SVS) of 92 out of 100, which shows the stock has tended to make larger-than-expected moves on the charts compared to what the options market had priced in. In other words, now may be an opportune time to speculate with near-term Endocyte options.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI